Canadian Cancer Trials Group Bulletins

General


Recent Publication

A recent study of the Canadian Cancer Trials Group's Working Group on Economic Analysis (WGEA) evaluating the cost-effectiveness of Cetuximab (Erbitux) in metastatic colorectal cancer shows that Cetuximab is more cost-effective for metastatic colorectal cancer when used for patients who don't have mutations in the KRAS gene, but may still not represent a good value.

The WGEA conducted this cost-effectiveness analysis using prospectively collected resource utilization and health utility data for patients in the CO.17 study who received cetuximab plus best supportive care (N = 283) or best supportive care alone (N = 274).

The full article can be accessed using this link ... http://jnci.oxfordjournals.org/cgi/content/abstract/djp232.

Additionally, Dr. Nicole Mittmann, lead author on the study, was interviewed by MedPage Today. You can read (and listen to) this interview by using this link ... http://www.medpagetoday.com/Gastroenterology/ColonCancer/15440?userid=163563&impressionId=1249881188674&utm_source=mSpoke&utm_medium=email&utm_campaign=DailyHeadlines&utm_content=Group1 .